Leopoldo Zambeletti is an experienced entrepreneur and investor in the life sciences sector, currently serving as the Founder of Grypania Holdings since September 2014, with a focus on investments in life sciences companies. Zambeletti holds board positions at several organizations, including Avanzanite Bioscience, Tema Sinergie, LenioBio GmbH, Touchlight, ADLER ORTHO S.R.L., and Philogen S.p.A., supporting innovations in orphan medicines, biotechnology, and medical devices. Additionally, Zambeletti is actively involved in corporate strategy at Nogra Pharma and founded 5x15 Italy, a platform for sharing inspirational stories. Education was completed at Università Commerciale Luigi Bocconi with a BA in Finance.
This person is not in any teams
This person is not in any offices
Avanzanite Bioscience
Founded by biopharmaceutical executives, Adam Plich and Anant Murthy, Avanzanite is on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word ‘Tanzanite’ – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian. The economic goal is to offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets. This is the unique expertise and core competency of our team following decades of operating experience navigating this area. Equally important, our humanitarian goals stem from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live. Avanzanite Bioscience B.V. is a fully authorized distributor of medicinal products within the European Economic Area, Switzerland and the UK, with a Wholesale Distributor Authorization (WDA) issued by Farmatec in the Netherlands.